跳至主要内容
临床试验/ACTRN12608000286347
ACTRN12608000286347招募中未知

A randomised trial of exercise training versus standard guideline-based care on vascular function in subjects with newly-diagnosed type 2 diabetes mellitus

Centre for Clinical Research & effective practice (CCRep)0 个研究点目标入组 32 人开始时间: 2008年6月4日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
32

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Open (masking not used)

入排标准

年龄范围
30 Years 至 59 Years(—)
性别
All

入选标准

  • •Patients to be included in this protocol must:
  • •1. Be aged >30 years and =60 years
  • •2. Have type 2 diabetes mellitus (maximum of 2 years since diagnosis) in accordance with American Diabetes Association criteria treated with diet or metformin oral hypoglycemic medication with an HbA1c 6.5-10% at baseline.
  • •3. Provide written informed consent to participate in the study

排除标准

  • •A patient with any of the following conditions prior to randomisation will not be enrolled into the study:
  • •1. Diabetic nephropathy (urine albumin creatinine ratio (ACR) >200mg/mmol)
  • •2. Known non-diabetic renal disease as indicated by haematuria, active urinary sediment or casts
  • •3. Serum creatinine >150 µmol/L in men and ?130 µmmol/L in women
  • •4. Morbid obesity with body mass >160kg
  • •5. Abnormal baseline Electrocardiogram (ECG), or inducible ischaemic changes on baseline exercise tolerance test
  • •6. Pregnant, nursing a child, or planning a pregnancy at the time of this study
  • •7. History of type 1 diabetes defined as age of onset <20 years and/or history of continuous treatment with insulin since diagnosis
  • •8. History of cigarette smoking, drug or alcohol abuse
  • •9. Co-morbid conditions that are likely t o affect ability to participate in an exercise program:
  • •a. Severe chronic obstructive pulmonary disease (COPD) as evidenced by hospitalization for decompensation within 6 months of randomization, chronic treatment with oral steroids, or a resting oxygen saturation (SAO2) <90 mm Hg
  • •b. Congestive heart failure (CHF) corresponding with New York Heart Association (NYHA) Class II, III and IV or an N-terminal pro-brain natriuretic peptide (NT-proBNP) level >350
  • •c. Severe ischaemic heart disease (IHD) with acute coronary event, and/or coronary artery bypass graft (CABG), and/or percutaneous coronary intervention (PCI) in the previous 60 days.
  • •d. Severe peripheral vascular disease
  • •e. Severe arthritic disease of the feet, knees, hips, or lower spine
  • •f. Severe liver disease with icterus and plasma bilirubin =60 µmmol/L, plasma transaminase = 3-fold upper limit of normal, albumin <30 g/L or coagulopathy
  • •g. Hematological disorders including hemoglobin <110 g/L or platelet count < 80,000/mm3
  • •10. Gastrointestinal bleeding in the previous 60 days,
  • •11. Malignancy other than basal cell carcinoma.
  • •12. Any other disease or condition which in the opinion of the investigator could make them unsuitable for entry.

研究者

发起方
Centre for Clinical Research & effective practice (CCRep)

相似试验